At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 396 enrolled
Drug / intervention
Liraglutide 3.0 mg +1 moredrug
Likely dose
Liraglutide 3.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
In Brief
A Phase 3 clinical trial evaluating Liraglutide 3.0 mg and Placebo for Metabolism and Nutrition Disorder and Obesity. Completed, enrolled 396 participants across 54 sites in 7 countries.
Detailed Summary
This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolism and Nutrition Disorder, Obesity
CountriesCanada, Germany, Israel, Italy, Mexico, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartFeb 2017
Primary CompletionSep 2018
Study CompletionSep 2018
TodayJul 2026
First PostedNov 15, 2016
Enrollment StartFeb 6, 2017
Primary CompletionSep 10, 2018
Study CompletionSep 25, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.6 years ago
Interventions
Liraglutide 3.0 mgdrug
Injected subcutaneously (s.c., under the skin) once daily
Placebodrug
Injected subcutaneously (s.c., under the skin) once daily